Together, metformin could inhibit the proliferation of MLL/AF9 AML cells by repressing OXPHOS, but whether other pathways such as AMPK/mTOR also contribute to the sensitivity of MLL/AF9 AML to metformin needs to be further explored. Here, KMT2A is linked to acute myeloid leukemia.